Key Metrics
3 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 16 |
| Article Processing Charges | USD 2390 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.
- 1 May 17
- Blood and lymphatic cancer : targets and therapy
-
Full paper
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.
- 1 Mar 16
- Blood and lymphatic cancer : targets and therapy
-
Full paper
Profile of elotuzumab and its potential in the treatment of multiple myeloma.
- 1 Jun 14
- Blood and lymphatic cancer : targets and therapy
Scite analysis
Powered by scite_
103 articles received 442 citations see all
- 8 Supporting
- 424 Mentioning
- 1 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 1 Errata
- 0 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
50%
4 to 6 months
50%
7 to 9 months
0%
Above 9 months
0%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY been actively publishing?
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY has been in operation since 2011 till date.
What is the publishing frequency of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY ?
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY published with a Continuous publication frequency.
How many articles did BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY publish last years ?
In 2023, BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY published articles.
What is the eISSN & pISSN for BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY ?
For BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY,eISSN is 1179-9889 and pISSN is1179-9889.
Who is the publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY ?
DOVE MEDICAL PRESS LTD is the publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY.